Abstract
Sweat parameters such as volume and chloride concentration may offer invaluable clinical insights for people with CF (PwCF). Pilocarpine-induced sweat collection for chloridometry measurement is the gold-standard for sweat chloride, but this technique is cumbersome and not suitable for remote settings. We have previously reported the utility of a skin-interfaced microfluidic device (CF Patch) in conjunction with a smartphone image processing platform that enables real-time measurement of sweating rates and sodium chloride loss in laboratory and remote settings. Here we conducted clinical studies characterizing the accuracy of the CF Patch compared to pilocarpine-induced sweat measurements using chloridometry and tested the feasibility of exercise-induced sweat chloride measurements in PwCF. The CF Patch demonstrated strong correlations compared to sweat chloride measured by chloridometry across clinic and remote settings and detected greater day-to-day sweat chloride variability in PwCF on CFTR modulators than healthy volunteers. These findings demonstrate that the CF Patch is suitable as a remote management device capable of measuring chloride concentrations and offers the potential of monitoring the efficacy of CF medication regimens.
Competing Interest Statement
A.J.A., R.G., and J.A.R. are co-founders of Epicore Biosystems, which develops and commercializes microfluidic devices for sweat analysis. D.E.W., J.C.W., and J.A.W. are currently employed by Epicore Biosystems. All other authors declare that they have no competing interests.
Funding Statement
Research reported in this publication was supported, in part, by the National Institutes of Health's National Center for Advancing Translational Sciences (Grant Number UL1TR001422) the National Heart, Lung, and Blood Institute Grant Number (R43HL162246).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Northwestern University Biomedical Institutional Review Board (IRB) (STU00215214).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos